Clinical trial · Interventional
Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Efficacy of Losartan in the Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side effects; it causes patients discomfort and pain and sometimes causes the termination of the chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the survival rate. One of the promising interventions in the prevention of PIPN is Losartan. Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive patients. There is strong evidence from different preclinical studies and retrospective cohort studies that Losartan has a neuroprotective effect. The purpose of our study is to investigate the efficacy of Losartan in the prevention of peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Peripheral Neuropathy Due to Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Losartan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Control arm
- description
- These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting
- type
- EXPERIMENTAL
- label
- Intervention arm
- description
- These patients will receive standard-of-care management for chemotherapy-induced nausea and vomiting plus losartan 100mg
- interventionNames
- Drug: Losartan
Primary outcomes (1)
- measure
- Development of paclitaxel-induced peripheral neuropathy
- timeFrame
- 12 weeks
- description
- Incidence and grading of paclitaxel-induced peripheral neuropathy (PIPN)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Females older than 18 years diagnosed with biopsy-confirmed breast cancer (Early breast cancer eligible for adjuvant or neoadjuvant) who are scheduled to receive paclitaxel 80 mg/m2. Exclusion Criteria: * Known hypersensitivity to Losartan. * Not Known Hypertensive patients * Not Known Diabetic patients * Treatment with Losartan/ARBs/ACE-I prior to the study. * Previous neuropathy * Renal impairment (Serum creatinine \> 2 mg/dl) * Significant liver disease: liver enzymes 2 folds the upper normal limit * Metastatic breast cancer * Pregnancy or lactation * Taking other medication for neuropathic pain * Significant Hypotension
References
Publications (1)
- DERIVEDMahmoud AMAS, Shash E, Ateyya H, Okasha FA, El Said NO. The Effect of Losartan in Preventing Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer: A Randomized, Controlled Study. Pharmacotherapy. 2026 Apr;46(4):e70124. doi: 10.1002/phar.70124. PMID 41800821